Bicara Therapeutics Common Stock Alpha and Beta Analysis
| BCAX Stock | 16.70 0.58 3.60% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Bicara Therapeutics Common. It also helps investors analyze the systematic and unsystematic risks associated with investing in Bicara Therapeutics over a specified time horizon. Remember, high Bicara Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Bicara Therapeutics' market risk premium analysis include:
Beta 0.9 | Alpha 0.7 | Risk 4.09 | Sharpe Ratio 0.0059 | Expected Return 0.0243 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Bicara Therapeutics Backtesting, Bicara Therapeutics Valuation, Bicara Therapeutics Correlation, Bicara Therapeutics Hype Analysis, Bicara Therapeutics Volatility, Bicara Therapeutics History and analyze Bicara Therapeutics Performance. Bicara Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Bicara Therapeutics market risk premium is the additional return an investor will receive from holding Bicara Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Bicara Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Bicara Therapeutics' performance over market.| α | 0.70 | β | 0.90 |
Bicara Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Bicara Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Bicara Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Bicara Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Bicara Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Bicara Therapeutics shares will generate the highest return on investment. By understating and applying Bicara Therapeutics stock market price indicators, traders can identify Bicara Therapeutics position entry and exit signals to maximize returns.
Bicara Therapeutics Return and Market Media
The median price of Bicara Therapeutics for the period between Thu, Oct 2, 2025 and Wed, Dec 31, 2025 is 17.15 with a coefficient of variation of 10.58. The daily time series for the period is distributed with a sample standard deviation of 1.78, arithmetic mean of 16.85, and mean deviation of 1.4. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 24000 shares by Cohlhepp Ryan of Bicara Therapeutics at 3.7898 subject to Rule 16b-3 | 10/06/2025 |
2 | Disposition of 8000 shares by Cohlhepp Ryan of Bicara Therapeutics at 3.7898 subject to Rule 16b-3 | 10/07/2025 |
3 | Disposition of 5627 shares by Hyep Ivan of Bicara Therapeutics at 3.7898 subject to Rule 16b-3 | 10/08/2025 |
4 | Disposition of 11445 shares by Mazumdar Claire of Bicara Therapeutics at 18.9205 subject to Rule 16b-3 | 10/13/2025 |
5 | Discretionary transaction by Ra Capital Management, L.p. of 1172334 shares of Bicara Therapeutics subject to Rule 16b-3 | 11/04/2025 |
6 | Wedbush Equities Analysts Lower Earnings Estimates for BCAX | 11/14/2025 |
7 | Disposition of 906 shares by Raben David of Bicara Therapeutics at 18.8424 subject to Rule 16b-3 | 11/25/2025 |
8 | Why Bicara Therapeutics Is Up 18.6 percent After FDA Breakthrough Therapy Designation for Cancer Drug | 11/26/2025 |
9 | Skandinaviska Enskilda Banken AB publ Acquires 61,201 Shares of Bicara Therapeutics Inc. BCAX | 12/03/2025 |
10 | Disposition of 9200 shares by Hyep Ivan of Bicara Therapeutics at 3.7898 subject to Rule 16b-3 | 12/22/2025 |
11 | Disposition of 9744 shares by Meisner Lara of Bicara Therapeutics at 5.45 subject to Rule 16b-3 | 12/26/2025 |
About Bicara Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Bicara or other stocks. Alpha measures the amount that position in Bicara Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2023 | 2024 | 2025 (projected) | Current Ratio | 0.21 | 15.32 | 27.93 | 29.33 | Net Debt To EBITDA | 0.11 | 4.42 | 7.22 | 7.58 |
Bicara Therapeutics Investors Sentiment
The influence of Bicara Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Bicara. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Bicara Therapeutics' public news can be used to forecast risks associated with an investment in Bicara. The trend in average sentiment can be used to explain how an investor holding Bicara can time the market purely based on public headlines and social activities around Bicara Therapeutics Common. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Bicara Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Bicara Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Bicara Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Bicara Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bicara Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bicara Therapeutics' short interest history, or implied volatility extrapolated from Bicara Therapeutics options trading.
Build Portfolio with Bicara Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.